Advertisement

OHSU and Cancer Research UK to collaborate on early detection

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE KNIGHT CANCER INSTITUTE at Oregon Health & Science University and Cancer Research UK formed an international collaboration focused on the early detection of cancer.

The collaboration seeks to address research models for the earliest stages of the disease; shortages of tissue samples available for research, especially samples from higher risk patients; and the need for a better understanding of the biology of early cancer and appropriate technologies to detect its features.

The collaboration will host an annual international conference series; in 2016, the conference will be titled “Cancer Research UK and OHSU Knight Cancer Institute present the Sondland-Durant Early Detection of Cancer Conference” in recognition of generous support from the Gordon D. Sondland and Katherine J. Durant Foundation.

Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement